四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00460 四环医药

已收盘 04-28 16:08:26

1.310

-0.010

-0.76%

最高1.340	最低1.300	成交量1,257万
今开1.310	昨收1.320	日振幅3.03%
总市值119.81亿	流通市值119.81亿	总股本91.46亿
成交额1,651万	换手率0.14%	流通股本91.46亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00460","market":"HK","secType":"STK","nameCN":"四环医药","latestPrice":1.31,"timestamp":1777363706002,"preClose":1.32,"halted":0,"volume":12571959,"delay":0,"changeRate":-0.007575757575757582,"floatShares":9146000000,"shares":9146000000,"eps":0.022575444742245418,"marketStatus":"已收盘","change":-0.01,"latestTime":"04-28 16:08:26","open":1.31,"high":1.34,"low":1.3,"amount":16511437,"amplitude":0.030303,"askPrice":1.31,"askSize":667000,"bidPrice":1.3,"bidSize":1051000,"shortable":3,"etf":0,"ttmEps":0.022575444742245418,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777426200000},"marketStatusCode":5,"adr":0,"listingDate":1288195200000,"exchange":"SEHK","adjPreClose":1.32,"dividendRate":0.017047,"openAndCloseTimeList":[[1777339800000,1777348800000],[1777352400000,1777363200000]],"volumeRatio":0.369409,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00460","defaultTab":"news","newsList":[{"id":"1100420636","title":"四环医药2025年扭亏为盈，医美与生物医药双轮驱动业绩显著提升","url":"https://stock-news.laohu8.com/highlight/detail?id=1100420636","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100420636?lang=zh_cn&edition=full","pubTime":"2026-04-27 16:45","pubTimestamp":1777279548,"startTime":"0","endTime":"0","summary":"四环医药于报告期内实现经营表现大幅改善，财务数据全面回升。2025年度收入达人民币26.18亿元，归属于公司权益持有人的溢利约人民币1.80亿元，成功扭转上年亏损局面。毛利同比增长45.1%至人民币18.02亿元，经营利润约人民币6.07亿元，较2024年同期经营亏损显著改善。公司在医美与生物医药双板块协同发力。医美收入约人民币14.85亿元，占总收入逾五成，同比增长近一倍；创新药业务收入约人民币1.76亿元，同比提升逾两倍。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"四环医药2025年扭亏为盈，医美与生物医药双轮驱动业绩显著提升","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629940080","title":"四环医药(00460)：受托人就股份奖励计划购买合共300万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629940080","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629940080?lang=zh_cn&edition=full","pubTime":"2026-04-21 18:33","pubTimestamp":1776767622,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药(00460)发布公告，于2026年4月21日，受托人已就股份奖励计划于市场上购买合共300万股本公司股份(股份)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"四环医药(00460)：受托人就股份奖励计划购买合共300万股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1600","BK1593","00460","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629096147","title":"港股异动 | 四环医药(00460)涨近3% 附属轩竹生物(02575)于AACR展示相关地罗阿克一线治疗研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629096147","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629096147?lang=zh_cn&edition=full","pubTime":"2026-04-21 11:32","pubTimestamp":1776742321,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，四环医药涨近3%，截至发稿，涨2.29%，报1.34港元，成交额1804.28万港元。消息面上，4月20日，四环医药发布公告，集团旗下非全资附属公司轩竹生物已在2026年 4月17日至2026年4月22日举行的2026年美国癌症研究协会年会以口头报告的形式展示地罗阿克一线治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌的临床III期研究结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","02575","00460","BK1515","BK4585","BK1593","BK1191","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109793411","title":"四环医药Dirozalkib一线治疗ALK阳性晚期非小细胞肺癌疗效优势显著","url":"https://stock-news.laohu8.com/highlight/detail?id=1109793411","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109793411?lang=zh_cn&edition=full","pubTime":"2026-04-20 12:03","pubTimestamp":1776657791,"startTime":"0","endTime":"0","summary":"四环医药旗下创新药Dirozalkib在一线治疗ALK阳性晚期非小细胞肺癌的临床研究中展现出显著的疗效优势。该药物在关键疗效指标上表现出色，为ALK阳性晚期非小细胞肺癌患者提供了新的治疗选择。临床数据显示，Dirozalkib在客观缓解率和无进展生存期等核心终点上均取得突破性进展。该药物有望为ALK阳性晚期非小细胞肺癌患者带来更优的治疗效果，同时也将进一步提升四环医药在肿瘤治疗领域的市场竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","00460","BK1515","BK1600","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154932036","title":"四环医药-轩竹生物在2026年AACR公布迪罗唑克针对ALK阳性非小细胞肺癌的III期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1154932036","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154932036?lang=zh_cn&edition=full","pubTime":"2026-04-20 12:02","pubTimestamp":1776657769,"startTime":"0","endTime":"0","summary":"四环医药旗下轩竹生物制药在2026年美国癌症研究协会（AACR）年会上，公布了其创新药物迪罗唑克（Dirozalkib）用于治疗ALK阳性非小细胞肺癌（NSCLC）的III期临床试验关键数据。\n此次公布的数据备受业界关注，为ALK阳性非小细胞肺癌患者提供了新的潜在治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1600","BK1191","BK1515","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628208795","title":"四环医药：获联交所批准轩竹生物H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2628208795","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628208795?lang=zh_cn&edition=full","pubTime":"2026-04-17 19:00","pubTimestamp":1776423600,"startTime":"0","endTime":"0","summary":"南财智讯4月17日电，四环医药（00460.HK）发布自愿公告，香港联合交易所于2026年4月16日批准其非全资附属公司轩竹生物科技有限公司（股份代号：02575.HK）实施H股全流通与转换及上市，涉及35724.58万股H股（即3.57亿股）的上市及买卖。该事项尚需待所有其他相关条件达成后方可完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604173709115295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK1593","02575","BK1600","BK1515","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626904465","title":"医美营收翻倍、创新药加速放量，四环医药（0460.HK）的成长拐点已至","url":"https://stock-news.laohu8.com/highlight/detail?id=2626904465","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626904465?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:02","pubTimestamp":1775721725,"startTime":"0","endTime":"0","summary":"医美业务以14.85亿元的营收、99.6%的同比增速，首次占据总营收比重突破50%（达57%），成为公司第一大收入来源","market":"us","thumbnail":"https://img7.gelonghui.com/column/7.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/7.png?guru_height=540&guru_width=375"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4355067","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["159992","00460","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625167946","title":"每周股票复盘：百奥赛图（688796）与四环医药战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2625167946","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625167946?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:32","pubTimestamp":1775327533,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，百奥赛图报收于112.3元，较上周的92.88元上涨20.91%。本周关注点公司公告汇总：百奥赛图与四环医药达成战略合作，聚焦减重等疾病领域创新药研发。公司公告汇总百奥赛图（北京）医药科技股份有限公司宣布与四环医药控股集团有限公司达成战略合作。双方将依托百奥赛图领先的全人抗体开发平台，结合四环医药在药物开发、生产和商业化方面的经验，围绕减重等多个疾病领域的创新药研发开展合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK1600","00460","BK1515","BK1593","BK1191","688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624251435","title":"港股公告掘金 | 百奥赛图-B与四环医药(00460)达成战略合作 加速减重等多领域创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2624251435","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624251435?lang=zh_cn&edition=full","pubTime":"2026-04-02 08:59","pubTimestamp":1775091553,"startTime":"0","endTime":"0","summary":"重大事项：百奥赛图-B(02315)与四环医药(00460)达成战略合作 加速减重等多领域创新药研发远东发展(00035)拟出售墨尔本丽思卡尔顿酒店49.9%权益大唐环境(01272)拟斥资约2457.41万元收购报废风电设备荣昌生物(09995)：国家药监局批准双特异性抗体药物偶联物(双抗ADC)注射用RC288开展临床试验易生活控股(00223)：与雅澳供应链启动AI数字供应链战略合作经营业绩","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU0254981946.USD","LU0531971595.HKD","LU1251922891.USD","LU0417516902.SGD","SG9999001226.SGD","LU0293314216.USD","BK1589","LU1242518931.SGD","BK1509","LU2294711713.HKD","BK1539","LU2097828805.USD","EVS.SI","LU0314109678.HKD","SG9999015986.USD","BK1161","LU0594300179.USD","BK1521","LU0823414551.USD","LU0588545904.SGD","LU0043850808.USD","LU2476274720.SGD","IE00BZ08YS42.EUR","81211","BK1191","LU1188198961.HKD","LU1808992512.USD","LU2399975544.HKD","LU0979878070.USD","LU2097828714.EUR","LU0143863198.USD","002594","LU0516423174.USD","LU2039709279.SGD","LU0634319403.HKD","LU0052750758.USD","LU1961090484.USD","BK0216","LU2357125470.USD","SG9999014674.SGD","LU0823426308.USD","GELYY","LU0039217434.USD","LU1868838027.USD","80175","LU0823426480.USD","SG9999015945.SGD","LU1282651048.USD","BK1540","BK1582","LU0164865239.USD","LU0823039010.USD","SG9999002828.SGD","LU0449509016.USD","LU0326950275.SGD","LU0315178854.USD","BK1600","LU1770034418.SGD","BK1594","LU0359201612.USD","SG9999006514.SGD","LU1023057109.AUD","IE00BZ08YT58.USD","LU0516422952.EUR","LU0531970944.HKD","BK1515","LU0211977185.USD","LU0463099449.HKD","LU0516422366.SGD","LU0561508036.HKD","LU0417516738.SGD","SG9999015952.SGD","LU2449936058.SGD","LU0289739343.SGD","LU0165289439.USD","LU1813983027.USD","LU0516422440.USD","LU0449515922.USD","BYDDY","LU0543330566.HKD","LU0593848301.USD","LU0244354667.USD","LU2249611893.SGD","LU1720050803.USD","SG9999006597.SGD","LU0540923850.HKD","LU1861219969.SGD","02315","LU1719994722.HKD","BK1574","LU0828238088.HKD","LU0516423091.SGD","SG9999015978.USD","LU0348735423.USD","LU1868837722.USD","LU0588545730.USD","LU1868837565.USD","LU0823414478.USD","LU0469268626.HKD","BK1593","LU0289961442.SGD","LU0214875030.USD","LU0588545490.SGD","LU0594300419.USD","LU0505663152.USD","LU2360107325.USD","LU0823038988.USD","LU2153592121.USD","688796","LU0348827113.USD","LU1224444064.USD","LU0509642566.USD","LU0865486749.SGD","LU1328277881.USD","LU0259732245.USD","LU0650527681.SGD","LU0315179316.USD","LU0348825331.USD","BK1610","BK4588","LU0572944931.SGD","LU1794554557.SGD","IE00BD6J9T35.USD","LU1880383440.USD","SG9999002463.SGD","LU0348805143.USD","LU0708995583.HKD","LU0164872284.USD","LU0819123356.HKD","LU1242518857.USD","LU1282651121.HKD","LU0359201885.HKD","LU0588546209.SGD","LU2506951792.HKD","LU0289960550.SGD","LU0871576103.HKD","LU0511384066.AUD","LU2097828474.EUR","LU2097828631.EUR","00460","LU1303224171.USD","LU0143863784.USD","LU0819121731.USD","HYDD.SI","LU0269904917.USD","LU0359202008.SGD","LU2097828557.USD","LU1861214812.USD","LU0229945570.USD","LU0856984785.SGD","LU2778985437.USD","LU0054450605.USD","IE00B0JY6N72.USD","BK1119","BK1124","BK1522","LU0320764599.SGD","LU2476274308.USD","LU0605514214.HKD","LU1880383366.USD","IE00BZ08YR35.GBP","LU0175139822.USD","LU0084288322.USD","LU0327786744.USD","LU2348774022.SGD","BK1240","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624540176","title":"智通港股早知道 | 美国执行载人绕月任务火箭发射升空 国际能源署署长：4月石油供应缺口将达到3月的两倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2624540176","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624540176?lang=zh_cn&edition=full","pubTime":"2026-04-02 07:33","pubTimestamp":1775086385,"startTime":"0","endTime":"0","summary":"美国执行载人绕月任务火箭发射升空当地时间4月1日傍晚，美国航空航天局新一代登月火箭“太空发射系统”从佛罗里达州肯尼迪航天中心发射升空，执行“阿耳忒弥斯2号”载人绕月任务。这是美国自1972年以来首次载人飞向月球。据知情人士透露，这家卫星制造与火箭发射公司已以保密方式递交上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","XOP","BK1191","LU1152091168.USD","LU0067412154.USD","BK1600","BK1515","LU1993786604.SGD","02315","BK1116","BK1194","BK1610","688796","BK4585","LU1807302812.USD","XLE","LU1960683339.HKD","03750","06681","02256","BK4570","LU0880133367.SGD","300750","BK1141","BK1161","03759","01857","LU1152091754.HKD","00460","300759","LU1008478684.HKD","BK4588","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624960675","title":"四环医药(00460)与百奥赛图(02315)达成战略合作 通过AI驱动的全人抗体研发平台加速减重等多领域创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2624960675","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624960675?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:06","pubTimestamp":1775034361,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药 发布公告，集团与百奥赛图(北京)医药科技股份有限公司正式签署战略合作协定。双方将立足优势互补与专业协同的合作原则，凭借集团在药物开发、规模化生产及商业化环节的全产业链成熟经验，结合百奥赛图业内领先的AI驱动全人抗体开发平台核心技术，在减重等多个高潜力疾病领域开展创新药物联合研发工作，建立长期稳定、互利共赢的合作关系，共同推动全球前沿创新药的研发落地与商业化布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1600","159992","BK0216","BK1161","CHAT","BK1191","AGIX","BK1574","688796","BK1593","00460","02315","06978","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140105347","title":"四环医药2026年3月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1140105347","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140105347?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:12","pubTimestamp":1775031141,"startTime":"0","endTime":"0","summary":"四环医药控股集团有限公司于2026年4月1日发布2026年3月股份变动月报。报告期为2026年3月1日至2026年3月31日，公告显示公司法定注册股本和已发行股份数未发生变化。截至3月31日，公司法定注册股本为100,000,000,000股，每股面值0.01港元，总额维持在HKD 1,000,000,000。已发行普通股股份数为9,145,988,206股，库藏股份数为184,011,000股，总股份数量9,329,999,206股与上个月末一致。报告期内未有新增发行、购回或注销。本月股本结构保持稳定。公告由执行董事及联席公司秘书陈燕玲签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167665830","title":"异动解读 | 四环医药盘中大涨5.88%，2025年业绩扭亏为盈且医美业务表现亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=1167665830","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167665830?lang=zh_cn&edition=full","pubTime":"2026-04-01 14:10","pubTimestamp":1775023841,"startTime":"0","endTime":"0","summary":"四环医药今日盘中股价大涨5.88%，引起了市场的广泛关注。消息面上，公司于盘前披露了2025年度业绩报告，业绩表现强劲成为股价上涨的主要驱动力。报告显示，公司全年实现营业收入26.18亿元，同比增长37.7%；年度溢利1.85亿元，成功实现扭亏为盈。其中，医美业务作为核心增长引擎，营收同比增长99.6%至14.85亿元，占总营收比重达到57%，其主打产品肉毒毒素乐提葆销量突破120万瓶，市占率稳居国内第二。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623637271","title":"四环医药(00460.HK)：2025年总收益同比上升37.7%达到26.18亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623637271","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623637271?lang=zh_cn&edition=full","pubTime":"2026-03-31 12:27","pubTimestamp":1774931221,"startTime":"0","endTime":"0","summary":"格隆汇3月31日丨四环医药公布2025年全年业绩，年内集团取得总收益约为人民币26.18亿元，同比上升约37.7%。其中收益的变化，主要来自医美业务驱动。填补细分市场空白，为医美业务收益贡献重要增量动力；同时，公司依托全品类合规产品矩阵布局，推行多品种组合行销策略，大力推动包括乐葆+、魔力童颜等组合方案，进一步推动整体销售规模快速提升，成为集团营收增长的第一驱动力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260331/32115228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1600","BK1593","00460","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623372607","title":"四环医药(00460)发布年度业绩 股东应占溢利约1.8亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2623372607","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623372607?lang=zh_cn&edition=full","pubTime":"2026-03-31 12:14","pubTimestamp":1774930466,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药 发布截至2025年12月31日止年度业绩，总收益约为人民币26.18亿元，同比上升约37.7%。毛利约为18.02亿元，同比上升约45.1%，整体研究及开发开支约为2.91亿元，同比下降38.5%。公司拥有人应占溢利约为1.8亿元，同比扭亏为盈;每股基本盈利1.97分。年内，医美业务的收益约为人民币14.85亿元，同比上升约 99.6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422790.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00460","BK1191","BK1593","BK1515","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198350764","title":"四环医药将于2026年7月16日派发末期股息每股0.0096元","url":"https://stock-news.laohu8.com/highlight/detail?id=1198350764","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198350764?lang=zh_cn&edition=full","pubTime":"2026-03-31 12:05","pubTimestamp":1774929956,"startTime":"0","endTime":"0","summary":"四环医药(00460)公告显示，董事会建议派发截至2025年12月31日止年度的末期股息，每股为人民币0.0096元，折合港币约0.0109元，并有待股东于2026年6月26日批准。\n除净日为2026年6月30日，股东如欲符合收取股息资格，必须于2026年7月2日16时30分前办理股份过户手续。股份过户登记将于2026年7月3日至2026年7月6日暂停办理，记录日期为2026年7月6日。股息预计于2026年7月16日派付。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162204148","title":"四环医药2025年度营收5,177.20万元，经调整净利润-2.46亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162204148","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162204148?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:12","pubTimestamp":1774872724,"startTime":"0","endTime":"0","summary":"四环医药公布截至2025年12月31日止年度财务数据。公告显示，营收为51,772千元，同比上一年度的30,094千元增长约72.06%。同期经调整净利润为-245,509千元，较上一年度的-556,430千元亏损幅度有所收窄。销售及分销开支为49,265千元，行政开支为77,817千元，两项费用均较上一年度有所下降。销售及分销开支相较于上年有一定幅度减少，行政开支降幅较为明显，从339,669千元降至77,817千元，显示在管理费用方面较上年同期减负明显。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621603174","title":"轩竹生物-B(02575)涨逾8% 安久卫治疗反流性食管炎III期试验完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2621603174","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621603174?lang=zh_cn&edition=full","pubTime":"2026-03-24 10:10","pubTimestamp":1774318245,"startTime":"0","endTime":"0","summary":"消息面上，四环医药发布公告，公司旗下非全资附属公司轩竹生物科技股份有限公司的创新药安奈拉唑钠肠溶片用于治疗成人反流性食管炎的中国III期临床试验已顺利完成全部500名受试者入组。据悉，安奈拉唑钠肠溶片于2023年6月获得中国国家药品监督管理局批准上市，用于患者治疗十二指肠溃疡。此次III期临床研究于2025年7月全面展开，近期完成受试者入组，标志着本公司在创新药物研发方面取得了重要进展。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977089","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK1600","BK1515","02575","BK1593","00460","BK1191","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621124714","title":"四环医药附属创新药III期临床试验完成500名受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2621124714","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621124714?lang=zh_cn&edition=full","pubTime":"2026-03-22 18:34","pubTimestamp":1774175640,"startTime":"0","endTime":"0","summary":"3月22日，四环医药（00460）发布公告，本公司旗下非全资附属公司轩竹生物科技股份有限公司的创新药安奈拉唑钠肠溶片（商品名：安久卫?）用于治疗成人反流性食管炎的中国III期临床试验已顺利完成全部500名受试者入组。该试验是一项多中心、随机、双盲双模拟、阳性药物平行对照的关键性研究，旨在评估安奈拉唑钠肠溶片治疗中国成年反流性食管炎受试者的有效性和安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603223679754978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00460","06978","BK1574","BK1600","III","BK4134","BK1161","BK1515","BK1191","BK1593","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618924904","title":"每日卖空追踪 | 四环医药 03月11日卖空量成交49.6万股，卖空比例为4.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618924904","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618924904?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:30","pubTimestamp":1773217813,"startTime":"0","endTime":"0","summary":"四环医药北京时间03月11日，跌1.34%，卖空量成交49.6万股，较上一交易日减少83.63%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163102a6b79262&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163102a6b79262&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1600","00460","BK1515","BK1593","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sihuanpharm.com.cn","stockEarnings":[{"period":"1week","weight":0.0076},{"period":"1month","weight":-0.0294},{"period":"3month","weight":-0.1429},{"period":"6month","weight":-0.0959},{"period":"1year","weight":1.0153},{"period":"ytd","weight":0.0732}],"compareEarnings":[{"period":"1week","weight":-0.0165},{"period":"1month","weight":0.039},{"period":"3month","weight":-0.0443},{"period":"6month","weight":-0.016},{"period":"1year","weight":0.1795},{"period":"ytd","weight":0.0115}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四环医药控股集团有限公司是一家主要从事研发、制造及销售医药产品和医美产品的投资控股公司。该公司通过三个分部运营其业务。医美产品分部包括填充类、塑形类、支撑类、补充类、光电设备类、体雕类、皮肤管理类及其他以及提供轻医美综合解决方案。创新药及其他药品分部从事研发及商业化糖尿病、乳腺癌、消化、肿瘤及非酒精性脂肪型肝炎等疾病领域的创新药。仿制药分部从事包括克林澳等仿制药的生产和销售。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.119825},{"month":2,"riseRate":0.5,"avgChangeRate":0.000395},{"month":3,"riseRate":0.3125,"avgChangeRate":-0.03194},{"month":4,"riseRate":0.533333,"avgChangeRate":0.040996},{"month":5,"riseRate":0.428571,"avgChangeRate":0.020898},{"month":6,"riseRate":0.571429,"avgChangeRate":0.003131},{"month":7,"riseRate":0.571429,"avgChangeRate":0.007501},{"month":8,"riseRate":0.5,"avgChangeRate":-0.014353},{"month":9,"riseRate":0.214286,"avgChangeRate":-0.045133},{"month":10,"riseRate":0.571429,"avgChangeRate":0.029461},{"month":11,"riseRate":0.466667,"avgChangeRate":0.008386},{"month":12,"riseRate":0.4,"avgChangeRate":-0.017588}],"exchange":"SEHK","name":"四环医药","nameEN":"SIHUAN PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"四环医药,00460,四环医药股票,四环医药股票老虎,四环医药股票老虎国际,四环医药行情,四环医药股票行情,四环医药股价,四环医药股市,四环医药股票价格,四环医药股票交易,四环医药股票购买,四环医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}